Integer Holdings Co. (NYSE:ITGR) Shares Sold by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado cut its holdings in Integer Holdings Co. (NYSE:ITGR) by 0.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 282,948 shares of the medical equipment provider’s stock after selling 817 shares during the period. Public Employees Retirement Association of Colorado owned about 0.84% of Integer worth $32,763,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Quest Partners LLC boosted its holdings in shares of Integer by 3,688.9% in the 2nd quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 332 shares during the period. GAMMA Investing LLC lifted its position in Integer by 60.9% in the 2nd quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 142 shares during the last quarter. Principal Securities Inc. bought a new stake in Integer in the 4th quarter valued at about $67,000. Headlands Technologies LLC bought a new stake in Integer in the 1st quarter valued at about $106,000. Finally, Innealta Capital LLC bought a new stake in Integer in the 2nd quarter valued at about $110,000. 99.29% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Integer

In other news, Director Jean M. Hobby sold 11,960 shares of Integer stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $119.66, for a total value of $1,431,133.60. Following the transaction, the director now owns 2,280 shares of the company’s stock, valued at approximately $272,824.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.00% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ITGR shares. Oppenheimer started coverage on shares of Integer in a research report on Tuesday, July 16th. They issued an “outperform” rating and a $135.00 price objective on the stock. Benchmark reiterated a “buy” rating and issued a $130.00 price objective on shares of Integer in a research report on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $133.86.

Integer Stock Up 2.4 %

ITGR stock opened at $131.48 on Friday. Integer Holdings Co. has a 52 week low of $69.40 and a 52 week high of $131.65. The company has a market capitalization of $4.41 billion, a price-to-earnings ratio of 45.49, a price-to-earnings-growth ratio of 1.81 and a beta of 1.09. The firm’s 50-day moving average is $122.80 and its two-hundred day moving average is $118.48. The company has a current ratio of 3.29, a quick ratio of 1.96 and a debt-to-equity ratio of 0.73.

Integer (NYSE:ITGR) last released its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $1.24 by $0.06. Integer had a net margin of 6.31% and a return on equity of 11.48%. The company had revenue of $436.20 million for the quarter, compared to the consensus estimate of $437.00 million. During the same period in the previous year, the firm earned $1.14 EPS. Integer’s revenue was up 9.0% on a year-over-year basis. On average, analysts forecast that Integer Holdings Co. will post 5.31 earnings per share for the current fiscal year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.